• Aliases: IDEC-C2B8; anti-CD20 monoclonal antibody
    • A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B-lymphocytes
    • FDA approved for the treatment of B-cell NHL and CLL
    • Currently in clinical trials for other hematologic malignancies
    • Recommended dose: IV infusion. 375 mg/m2 for NHL. 375 mg/m2 first cycle and 500 mg/m2 in cycles 2 to 6, in combination with fludarabine and cyclophosphamide, administered every 28 days
    • Half-life: 22 days (range 6–52 days) in NHL; 32 days (range 14–62 days) in CLL
    Other topics in Targeted and Immunotherapy Agents